A new trading day began on Friday, with Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) stock price up 9.99% from the previous day of trading, before settling in for the closing price of $16.41. ARCT’s price has ranged from $14.30 to $45.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 379.70% over the last five years. Meanwhile, its annual earnings per share averaged -143.22%. With a float of $24.34 million, this company’s outstanding shares have now reached $27.08 million.
The firm has a total of 180 workers. Let’s measure their productivity. In terms of profitability, gross margin is 104.5%, operating margin of -37.74%, and the pretax margin is -40.69%.
Arcturus Therapeutics Holdings Inc (ARCT) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Arcturus Therapeutics Holdings Inc is 9.27%, while institutional ownership is 89.86%. The most recent insider transaction that took place on Oct 15 ’24, was worth 249,121. In this transaction Chief Scientific Officer & COO of this company sold 12,000 shares at a rate of $20.76, taking the stock ownership to the 435,334 shares. Before that another transaction happened on Oct 15 ’24, when Company’s Officer proposed sale 12,000 for $20.76, making the entire transaction worth $249,121.
Arcturus Therapeutics Holdings Inc (ARCT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -143.22% per share during the next fiscal year.
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) Trading Performance Indicators
Here are Arcturus Therapeutics Holdings Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.21, a number that is poised to hit -0.55 in the next quarter and is forecasted to reach -2.15 in one year’s time.
Technical Analysis of Arcturus Therapeutics Holdings Inc (ARCT)
Analysing the last 5-days average volume posted by the [Arcturus Therapeutics Holdings Inc, ARCT], we can find that recorded value of 0.46 million was better than the volume posted last year of 0.42 million. As of the previous 9 days, the stock’s Stochastic %D was 43.69%. Additionally, its Average True Range was 1.32.
During the past 100 days, Arcturus Therapeutics Holdings Inc’s (ARCT) raw stochastic average was set at 32.38%, which indicates a significant decrease from 76.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 80.17% in the past 14 days, which was higher than the 69.74% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.07, while its 200-day Moving Average is $21.90. Now, the first resistance to watch is $19.12. This is followed by the second major resistance level at $20.20. The third major resistance level sits at $21.51. If the price goes on to break the first support level at $16.74, it is likely to go to the next support level at $15.43. Should the price break the second support level, the third support level stands at $14.35.
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) Key Stats
With a market capitalization of 488.97 million, the company has a total of 27,087K Shares Outstanding. Currently, annual sales are 166,800 K while annual income is -29,730 K. The company’s previous quarter sales were 41,670 K while its latest quarter income was -6,900 K.
